Adocia Opens a Subsidiary in the USA and is Pleased to Appoint Simon Bruce, MD and Stephen Daly

Regulatory News:

ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC) announced today the creation of a subsidiary in the USA, Adocia Incorporated, and the accompanying appointments of Simon Bruce, MD and Stephen Daly.

Opening a US subsidiary is a key step in Adocia’s strategy, the USA are currently the primary market for its products. Adocia has developed BioChaperone® pipeline products in order to improve the insulin based treatments for diabetes, monoclonal antibodies and growth factors for the diabetic foot ulcer healing. Last December 2014, Adocia announced an alliance with Eli Lilly to co-develop BioChaperone Lispro, which is one of its products for the treatment of diabetes.¹

« The opening of a US subsidiary is crucial in order to increase our efforts on this priority market. Our development axis are to intensify our efforts in partnerships, to build relationships with the main key opinion leaders, specialized in the diabetes as well as in the wound healing fields in order to assert the medical benefit of our innovative formulations and eventually increase links with the US financial community, » says Gérard Soula, CEO of Adocia.

Two employees are already appointed, Simon Bruce, M.D., Chief Medical Officer and Stephen Daly, US Commercial Lead who is in charge of the business development in the USA and also of the US investors relations.

Dr. Bruce, who originally trained in endocrine clinical research at the National Institutes of Health in Bethesda, MD, has over 15 years of experience drug development and registrational drug trials. In his last job at Halozyme Pharmaceuticals, Dr Bruce held a position as an Executive Medical Director working on the ultra-rapid insulin program. He was in charge of the regulatory strategy and led numerous interactions with the Food and Drug Administration (FDA). Previously at Amylin Pharmaceuticals, he was in charge of the phase 3 studies and safety analysis in the development in the USA of Bydureon, which is a once-weekly GLP-1 analog injectable formulation.

Stephen Daly has 24 years of experience in commercialization and business development for pharmaceutical and biotech products across multiple therapeutic categories. Most recently, he served as the Vice President of Commercial at Halozyme Therapeutics for their ultra-rapid insulin program. Stephen Daly’s experience in the diabetes field also includes several years at Amylin Pharmaceuticals in marketing and brand leadership for Byetta® and Symlin®

« Their knowledge and experience in the drug development, especially in the diabetes field, are unique from both medical and commercial perspectives. They are indisputable assets to accelerate the development and commercialization of our projects and to optimize our collaborative research in partnerships. » adds Olivier Soula, R&D director and deputy general manager.

About Adocia

To be a global leader in the innovative delivery of insulins and therapeutic proteins

ADOCIA is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. ADOCIA’s proprietary BioChaperone^® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, ADOCIA signed a partnership with the company Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

ADOCIA will continue to develop its fast-acting human insulin formulation internally. ADOCIA is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. A dose-response clinical study (Phase IIa) is scheduled for the first quarter of 2015.

Besides, in August 2014, ADOCIA launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB).

ADOCIA has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). ADOCIA is engaged in collaborative programs with two major pharmaceutical companies in this field.

Fighting cancer with targeted treatments

DriveIn^® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« Innovative medicine for everyone, everywhere »

ADOCIA’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

ADOCIA is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing ADOCIA common stock are traded on the US OTC market under the ticker symbol ADOCY.
For more information, visit: www.adocia.com

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors” section of the Reference Document registered by the French Autorité des marchés financiers (Financial Markets Authority) on April 24, 2014 under number R14-020 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained therein do not constitute an offer to sell, nor the solicitation of an offer to purchase or subscribe for, ADOCIA shares in any country.

¹ Adocia press release dated December 19, 2014: Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology